Strategic funding invIOs has secured a Series A of approximately €8.2 million and recent financing of $8.94 million, indicating traction and potential for growth partnerships to accelerate its pipeline in immuno-oncology.

Collaborative potential Active collaborations with prestigious institutions like the Dana-Farber Cancer Institute and universities on glioblastoma, plus a newly formed Scientific Advisory Board, create partnerable avenues for co-development, joint research, and access to clinical and translational expertise.

Early-stage focus The company concentrates on discovery and pre-clinical development with the aim to advance assets into clinical trials, presenting opportunities for CROs, assay development partners, and technology providers to support early-phase activities.

Immuno-oncology niche Specialization in immune-system activation against solid tumors and personalized approaches positions invIOs for partnerships around small molecules or biologics targeting glioblastoma and related indications, appealing to specialty biotech buyers.

Global exposure With a Vienna-based global outreach, a private biotech focus, and a mix of European leadership and advisory experts, there are sales opportunities for regional market access, IP management services, and international clinical trial support solutions.